Cargando…

Transcutaneous electrical acupoint stimulation for children with attention-deficit/hyperactivity disorder: a randomized clinical trial

Little is known about the effects of transcutaneous electrical acupoint stimulation (TEAS) for children with attention-deficit/hyperactivity disorder (ADHD). Here, we carried out a 4 week randomized clinical trial in which patients aged 6–12 years old with an ADHD diagnosis received TEAS or sham TEA...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhuo, Lixia, Zhao, Xiaoyan, Zhai, Yifang, Zhao, Boqiang, Tian, Lin, Zhang, Yannan, Wang, Xiaodan, Zhang, Tingyu, Gan, Xinyi, Yang, Cheng, Wang, Weigang, Gao, Wei, Wang, Qiang, Rohde, Luis Augusto, Zhang, Jie, Li, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9022403/
https://www.ncbi.nlm.nih.gov/pubmed/35449191
http://dx.doi.org/10.1038/s41398-022-01914-0
_version_ 1784690076154855424
author Zhuo, Lixia
Zhao, Xiaoyan
Zhai, Yifang
Zhao, Boqiang
Tian, Lin
Zhang, Yannan
Wang, Xiaodan
Zhang, Tingyu
Gan, Xinyi
Yang, Cheng
Wang, Weigang
Gao, Wei
Wang, Qiang
Rohde, Luis Augusto
Zhang, Jie
Li, Yan
author_facet Zhuo, Lixia
Zhao, Xiaoyan
Zhai, Yifang
Zhao, Boqiang
Tian, Lin
Zhang, Yannan
Wang, Xiaodan
Zhang, Tingyu
Gan, Xinyi
Yang, Cheng
Wang, Weigang
Gao, Wei
Wang, Qiang
Rohde, Luis Augusto
Zhang, Jie
Li, Yan
author_sort Zhuo, Lixia
collection PubMed
description Little is known about the effects of transcutaneous electrical acupoint stimulation (TEAS) for children with attention-deficit/hyperactivity disorder (ADHD). Here, we carried out a 4 week randomized clinical trial in which patients aged 6–12 years old with an ADHD diagnosis received TEAS or sham TEAS. The primary outcome measure was the investigator-rated Clinical Global Impression-Improvement (CGI-I) score at week 4. Secondary outcomes included changes from baseline to week 4 in the investigator-rated Clinical Global Impression-Severity of Illness (CGI-S) score, the Conners’ Parent/Teacher Rating Scales-Revised: Short Form (CPRS-R: S/CTRS-R: S) score, go/no-go task performance, and functional near-infrared spectroscopy (fNIRS)-based oxygenated hemoglobin level within the prefrontal cortex. At week 4, the CGI-I score indicated improvement in 33.3% of the TEAS group compared with 7.7% of the sham group (P = 0.005). The TEAS group had a greater decrease in the mean CGI-S score (−0.87) than the sham TEAS group (−0.28) (P = 0.003). A greater enhancement in the mean cerebral oxygenated hemoglobin within the prefrontal cortex was found in the TEAS group (0.099 mM mm) compared with the sham TEAS group (0.005 mM mm) (P < 0.001). CPRS-R: S score, CTRS-R: S score, and go/no-go performance exhibited no significant improvement after TEAS treatment. The manipulation-associated adverse events were uncommon in both groups, and events were very mild. Our results show that noninvasive TEAS significantly improved general symptoms and increased prefrontal cortex blood flow within 4 weeks for children with ADHD. Further clinical trials are required to understand the long-term efficacy in a larger clinical sample. This trial was registered on ClinicalTrials.gov (NCT 03917953).
format Online
Article
Text
id pubmed-9022403
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-90224032022-04-21 Transcutaneous electrical acupoint stimulation for children with attention-deficit/hyperactivity disorder: a randomized clinical trial Zhuo, Lixia Zhao, Xiaoyan Zhai, Yifang Zhao, Boqiang Tian, Lin Zhang, Yannan Wang, Xiaodan Zhang, Tingyu Gan, Xinyi Yang, Cheng Wang, Weigang Gao, Wei Wang, Qiang Rohde, Luis Augusto Zhang, Jie Li, Yan Transl Psychiatry Article Little is known about the effects of transcutaneous electrical acupoint stimulation (TEAS) for children with attention-deficit/hyperactivity disorder (ADHD). Here, we carried out a 4 week randomized clinical trial in which patients aged 6–12 years old with an ADHD diagnosis received TEAS or sham TEAS. The primary outcome measure was the investigator-rated Clinical Global Impression-Improvement (CGI-I) score at week 4. Secondary outcomes included changes from baseline to week 4 in the investigator-rated Clinical Global Impression-Severity of Illness (CGI-S) score, the Conners’ Parent/Teacher Rating Scales-Revised: Short Form (CPRS-R: S/CTRS-R: S) score, go/no-go task performance, and functional near-infrared spectroscopy (fNIRS)-based oxygenated hemoglobin level within the prefrontal cortex. At week 4, the CGI-I score indicated improvement in 33.3% of the TEAS group compared with 7.7% of the sham group (P = 0.005). The TEAS group had a greater decrease in the mean CGI-S score (−0.87) than the sham TEAS group (−0.28) (P = 0.003). A greater enhancement in the mean cerebral oxygenated hemoglobin within the prefrontal cortex was found in the TEAS group (0.099 mM mm) compared with the sham TEAS group (0.005 mM mm) (P < 0.001). CPRS-R: S score, CTRS-R: S score, and go/no-go performance exhibited no significant improvement after TEAS treatment. The manipulation-associated adverse events were uncommon in both groups, and events were very mild. Our results show that noninvasive TEAS significantly improved general symptoms and increased prefrontal cortex blood flow within 4 weeks for children with ADHD. Further clinical trials are required to understand the long-term efficacy in a larger clinical sample. This trial was registered on ClinicalTrials.gov (NCT 03917953). Nature Publishing Group UK 2022-04-21 /pmc/articles/PMC9022403/ /pubmed/35449191 http://dx.doi.org/10.1038/s41398-022-01914-0 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Zhuo, Lixia
Zhao, Xiaoyan
Zhai, Yifang
Zhao, Boqiang
Tian, Lin
Zhang, Yannan
Wang, Xiaodan
Zhang, Tingyu
Gan, Xinyi
Yang, Cheng
Wang, Weigang
Gao, Wei
Wang, Qiang
Rohde, Luis Augusto
Zhang, Jie
Li, Yan
Transcutaneous electrical acupoint stimulation for children with attention-deficit/hyperactivity disorder: a randomized clinical trial
title Transcutaneous electrical acupoint stimulation for children with attention-deficit/hyperactivity disorder: a randomized clinical trial
title_full Transcutaneous electrical acupoint stimulation for children with attention-deficit/hyperactivity disorder: a randomized clinical trial
title_fullStr Transcutaneous electrical acupoint stimulation for children with attention-deficit/hyperactivity disorder: a randomized clinical trial
title_full_unstemmed Transcutaneous electrical acupoint stimulation for children with attention-deficit/hyperactivity disorder: a randomized clinical trial
title_short Transcutaneous electrical acupoint stimulation for children with attention-deficit/hyperactivity disorder: a randomized clinical trial
title_sort transcutaneous electrical acupoint stimulation for children with attention-deficit/hyperactivity disorder: a randomized clinical trial
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9022403/
https://www.ncbi.nlm.nih.gov/pubmed/35449191
http://dx.doi.org/10.1038/s41398-022-01914-0
work_keys_str_mv AT zhuolixia transcutaneouselectricalacupointstimulationforchildrenwithattentiondeficithyperactivitydisorderarandomizedclinicaltrial
AT zhaoxiaoyan transcutaneouselectricalacupointstimulationforchildrenwithattentiondeficithyperactivitydisorderarandomizedclinicaltrial
AT zhaiyifang transcutaneouselectricalacupointstimulationforchildrenwithattentiondeficithyperactivitydisorderarandomizedclinicaltrial
AT zhaoboqiang transcutaneouselectricalacupointstimulationforchildrenwithattentiondeficithyperactivitydisorderarandomizedclinicaltrial
AT tianlin transcutaneouselectricalacupointstimulationforchildrenwithattentiondeficithyperactivitydisorderarandomizedclinicaltrial
AT zhangyannan transcutaneouselectricalacupointstimulationforchildrenwithattentiondeficithyperactivitydisorderarandomizedclinicaltrial
AT wangxiaodan transcutaneouselectricalacupointstimulationforchildrenwithattentiondeficithyperactivitydisorderarandomizedclinicaltrial
AT zhangtingyu transcutaneouselectricalacupointstimulationforchildrenwithattentiondeficithyperactivitydisorderarandomizedclinicaltrial
AT ganxinyi transcutaneouselectricalacupointstimulationforchildrenwithattentiondeficithyperactivitydisorderarandomizedclinicaltrial
AT yangcheng transcutaneouselectricalacupointstimulationforchildrenwithattentiondeficithyperactivitydisorderarandomizedclinicaltrial
AT wangweigang transcutaneouselectricalacupointstimulationforchildrenwithattentiondeficithyperactivitydisorderarandomizedclinicaltrial
AT gaowei transcutaneouselectricalacupointstimulationforchildrenwithattentiondeficithyperactivitydisorderarandomizedclinicaltrial
AT wangqiang transcutaneouselectricalacupointstimulationforchildrenwithattentiondeficithyperactivitydisorderarandomizedclinicaltrial
AT rohdeluisaugusto transcutaneouselectricalacupointstimulationforchildrenwithattentiondeficithyperactivitydisorderarandomizedclinicaltrial
AT zhangjie transcutaneouselectricalacupointstimulationforchildrenwithattentiondeficithyperactivitydisorderarandomizedclinicaltrial
AT liyan transcutaneouselectricalacupointstimulationforchildrenwithattentiondeficithyperactivitydisorderarandomizedclinicaltrial